Fourth Quarter & Full Year 2022 Financial & Business Update
We Anticipate Durability Data Mid-2023 for Novel, Wholly-Owned
SGN-B6A in Large Tumor Types
SGN-B6A
Wholly-owned, first-in-class vedotin ADC
Targets integrin beta-6, overexpressed in
range of solid tumors
Antibody engineered for high target
selectivity, limiting binding to other
integrins
• Interim phase 1 monotherapy results
show encouraging anti-tumor activity with
tolerable safety profile
Expansion cohorts ongoing in NSCLC,
esophageal, and head and neck cancers
Seagen
Sum of Diameters (Maximum % Change from Baseline)
NSCLC Subset, Dose Escalation¹
Median 3.5 (range: 1 - 8) lines of prior therapy²
100
Treatment Ongoing
Q3W
1.8 mg/kg
2Q3W
1.2 mg/kg
2Q4W
80-
1.25 mg/kg
1.5 mg/kg
1.8 mg/kg
Q1W
1.0 mg/kg
1.2 mg/kg
2.0 mg/kg
60
40
20
0
-20
-40
NSCLC N=27
-60
-80
CORR, n (%)
95% CI
9 (33.3)
(16.5, 54.0)
-100
*
Individual Patients (N=27)
*
*
*
1 Hollebecque, et al, SITC 2022, Abstract No. 731; not approved for use; most common TEAEs were fatigue (36.7%), nausea (34.2%) and diarrhea (29.1%); 2 Prior therapy includes platinum and anti-PD/L-1 therapy.
In patients with driver mutations prior therapy includes TKI and cytotoxic therapy
20%
-30%
27
27View entire presentation